Abstract
Serotonin (5-hydroxytryptamine, 5-HT) participates in several functions of the gastrointestinal tract. Receptors in seven families (5-HT1-5-HT7) were identified, many of which are present on enterocytes, intrinsic and extrinsic neurons, interstitial cells, and gut myocytes. Most 5-HT is released from enterochromaffin cells in response to physiologic and pathologic stimuli. Roles of 5-HT in health include control of normal gut motor activity, secretion, and sensation, and regulation of food intake and cell growth. Abnormalities of serotonergic function contribute to symptom genesis in functional bowel disorders, inflammatory and infectious diseases of the gut, emetic responses to varied stimuli, obesity, and dysregulation of cell growth. Therapies acting as agonists or antagonists of 5-HT receptors or that modulate 5-HT reuptake play prominent roles in managing these conditions, although use of many agents is hampered by cardiopulmonary complications. Novel agents are in testing, which may exhibit efficacy without significant toxicity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Tonini M: 5-Hydroxytryptamine effect in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 2005, 17:637–642.
Van Lelyveld N, Ter Linde J, Schipper ME, Samsom M: Regional differences in expression of TPH-1, SERT, 5-HT3, and 5-HT4 receptors in the human stomach and duodenum. Neurogastroenterol Motil 2007, 19:342–348.
Holbrook JD, Gill CH, Zebda N, et al.: Characterization of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 2009, 108:384–396.
Gershon MD, Tack J: The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397–414.
Kidd M, Modlin IM, Gustafsson BI, et al.: Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008, 295:G260–G272.
Chen JJ, Li ZS, Pan H, et al.: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001, 21:6348–6361.
Tack J, Vanden Berghe P, Coulie B, et al.: Sumatriptan is an agonist at 5-HT1P receptors on myenteric neurons in the guinea pig gastric antrum. Neurogastroenterol Motil 2007, 19:39–46.
Bjornsson ES, Chey WD, Hooper F, et al.: Impaired gastrocolonic response and peristaltic reflex in slow transit constipation: role of 5-HT3 pathways. Am J Physiol 2002, 283:G400–G407.
Camilleri M, Atanasova E, Carlson PJ, et al.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002, 123:425–432.
Berman SM, Chang L, Suyenobu B, et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002, 123:969–977.
Sabate JM, Bouhassira D, Poupardin C, et al.: Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008, 20:134–141.
Beattie DT, Smith JA: Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:181–203.
Gwynne RM, Ellis M, Sjovall H, Bornstein JC: Cholera toxin induces sustained hyperexcitability in submucosal secretomotor neurons in guinea pig jejunum. Gastroenterology 2009, 136:299–308.
Hirata T, Keto Y, Nakata M, et al.: Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats. Eur J Pharmacol 2008, 587:281–284.
Garfield AS, Heisler LK: Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009, 587:49–60.
Halford JC, Harrold JA, Boyland EJ, et al.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27–55.
Bouwknecht JA, van der Gugten J, Hijzen TH, et al.: Male and female 5-HT1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001, 74:507–516.
Woolley ML, Bentley JC, Sleight AJ, et al.: A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210–219.
Nakamura K, Sato T, Ohashi A, et al.: Role of a serotonin precursor in development of gut microvilli. Am J Pathol 2008, 172:333–344.
Yadav VK, Ryu JH, Suda N, et al.: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825–837.
Wouters MM, Gibbons SJ, Roeder JL, et al.: Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors. Gastroenterology 2007, 133:897–906.
Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657–1664.
Coleman N, Foley S, Dunlop SP, et al.: Abnormalities of serotonin metabolism and its relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006, 4:874–881.
Costedio MM, Coates MD, Danielson AB, et al.: Serotonin signaling in diverticular disease. J Gastrointest Surg 2008, 12:1439–1445.
Wang H, Steeds J, Motomura Y, et al.: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007, 56:949–957.
Dunlop SP, Coleman NS, Blackshaw E, et al.: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349–357.
Van Lelyveld N, Ter Linde J, Schipper M, Samsom M: Serotonergic signaling in the stomach and duodenum of patients with gastroparesis. Neurogastroenterol Motil 2008, 20:448–455.
Van Kerkhoven LA, Laheij RJ, Jansen JB: Meta-analysis: a functional polymorphism in the serotonin transporter gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:979–986.
Kapeller J, Houghton LA, Monnikes H, et al.: First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Molec Gen 2008, 17:2967–2977.
Carmani NA, Crim JL, Janoyan JJ, et al.: A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res 2009, 1248:40–58.
Nocito A, Dahm F, Jochum W, et al.: Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008, 68:5152–5158.
Andresen V, Montori VM, Keller J, et al.: Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545–555.
Chang L, Chey W, Harris L, et al.: Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006, 101:1069–1079.
Camilleri M: Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007, 19:77–84.
De Maeyer JH, Lefebvre RA, Schuurkes JA: 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008, 20:99–112.
Li Y, Nie Y, Xie J, et al.: The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence of tegaserod treatment in Chinese patients. Dig Dis Sci 2007, 52:2942–2949.
Pasricha PJ: Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007, 132:2287–2290.
Camilleri M, Kerstens R, Rykx A, Vandeplassche l: A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008, 358:2344–2354.
Spiller RC, Meyers NL, Hickling RI: Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled trial. Dig Dis Sci 2008, 53:3191–3200.
Kim HS, Choi EJ, Park H: The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008, 20:169–176.
Evangelista S: Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Invest Drugs 2007, 8:416–422.
Vera-Portocarrero LP, Ossipov MH, King T, Porreca F: Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 2008, 135:1369–1378.
Tack J, Broekaert D, Fischler B, et al.: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006, 55:1095–1103.
Halpert A, Dalton CB, Diamant NE, et al.: Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005, 100:664–671.
Jordan K, Schmoll HJ, Aapro MS: Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007, 61:162–175.
Smith BM, Thomsen WJ, Grottick AJ: The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin Invest Drugs 2006, 15:257–266.
Heal DJ, Smith SL, Fisas A, et al.: Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharm Ther 2008, 117:207–231.
Xu W, Tanim H, Shapiro S, et al.: Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 2006, 7:301–308.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasler, W.L. Serotonin and the GI tract. Curr Gastroenterol Rep 11, 383–391 (2009). https://doi.org/10.1007/s11894-009-0058-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-009-0058-7